SCHEMBL751320

SCHEMBL751320

CC(C)(C)C(=O)ONCCNS(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 2/20 0.52
TSHR P16473 1/20 0.48
KMT2A Q03164 1/20 0.44
POLB P06746 2/20 0.43
USP2 O75604 1/20 0.43
F2 P00734 2/20 0.43
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CYP2C19 P33261 1/20 0.40
GFER P55789 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
PRSS1 P07477 1/20 0.40
PRSS2 P07478 1/20 0.40
PRSS3 P35030 1/20 0.40
TBXA2R P21731 1/20 0.39
PKM P14618 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3799644 0.77 MEP1B (0.53) MEP1BTSHRKMT2AF2MAPT
SCHEMBL23787605 0.75 MEP1B (0.65) MEP1BTSHRKMT2APOLBUSP2
SCHEMBL7673440 0.75 MEP1B (0.60) MEP1BTSHRKMT2APOLBF2
SCHEMBL13543488 0.75 ALDH1A1 (0.69) MEP1BTSHRKMT2APOLBMAPT
SCHEMBL1018445 0.74 CYP2C19 (0.67) MEP1BTSHRKMT2APOLBUSP2
SCHEMBL3103190 0.73 MEP1B (0.67) MEP1BTSHRKMT2AMAPTSMN1; SMN2
SCHEMBL751486 0.72 MEP1B (0.65) MEP1BTSHRKMT2AF2CYP2C19
SCHEMBL3054739 0.72 ALDH1A1 (0.65) MEP1BTSHRKMT2AF2SMN1; SMN2
SCHEMBL15754748 0.72 TSHR (0.65) MEP1BTSHRKMT2APOLBSMN1; SMN2
SCHEMBL13766688 0.72 MEP1B (0.60) MEP1BTSHRKMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138209-B2 Substituted picolinamides as MAO-B inhibitors useful for treating obesity JENRIN DISCOVERY, INC. (US) 2012-03-20 US disclosed
US-8138209-B2 Substituted picolinamides as MAO-B inhibitors useful for treating obesity JENRIN DISCOVERY, INC. (US) 2012-03-20 US disclosed
WO-2007008963-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-01-18 WO disclosed
US-20070015734-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-01-18 US disclosed
US-20070015734-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015734-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 MEP1B 1383/4885TSHR 1111/4885KMT2A 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.